Mizuho reiterates Braze stock rating on strong Q2 results

Braze reported fiscal Q2 revenue of $227.2 million, up 26% year over year and roughly $7 million above consensus, while adjusted EPS of $0.19 beat the $0.15 expectation. Non-GAAP operating margin reached 9.7%, exceeding the 8.1% consensus and expanding more than 600bps year over year; management raised fiscal 2027 revenue-growth guidance to about 23% from 21% and lifted margin guidance. Q3 margin guidance was below consensus due to Forge conference costs and sales-capacity investment, but bookings, upsells and AI-product adoption remained strong; Mizuho retained its Outperform rating and $32 target, while other analysts cited targets of $35 to $50.

Analysis

The investable question is whether Braze can sustain mid-20% growth while converting its expanding sales footprint into durable operating leverage. The near-term margin guide creates an execution gap: if incremental sales hiring does not translate into pipeline conversion by the next two earnings reports, investors will likely re-rate BRZE as a mature marketing-software vendor rather than reward it for a renewed growth cycle. That is especially material for a sub-$4B SaaS name, where a modest multiple reset can outweigh an earnings beat.

Competitive takeaways and upsell are the important claims to diligence, not the headline beat. If verified through net revenue retention, large-customer additions and sales-cycle duration, Braze is likely taking share from point-solution incumbents such as TWLO/Segment, ZETA and Iterable rather than merely benefiting from easier comparisons. AI adoption is not yet a standalone valuation catalyst; it matters only if it lowers campaign-production labor, improves conversion outcomes, or supports premium packaging without increasing inference costs enough to dilute gross margin.

Consensus price targets imply limited asymmetry after the post-results validation, while the stock sits close to the lower end of published targets. The better setup is to wait for evidence that the investment-led margin dip is temporary: sustained organic growth above 23%, stable-to-improving retention, and a re-acceleration in forward bookings would support a higher-growth peer multiple over the next 6-12 months. Conversely, a second consecutive organic-growth deceleration or weaker fiscal-year margin outlook would falsify the thesis and likely expose BRZE to a 15-25% de-rating.

Key Decisions for Investors

• Maintain a watch-list long rather than chase immediately; initiate BRZE only after the next earnings release confirms organic growth at or above 23% and management reiterates the path to fiscal-year margin expansion. Target 20-30% upside over 6-12 months if execution supports multiple expansion; exit on organic growth below 20% or a material cut to profitability guidance.
• For exposure ahead of the next report, use a defined-risk bullish structure: buy a 6-9 month BRZE call spread with the long strike near spot and short strike around $37-$40. This captures a confirmation-driven re-rating while limiting downside if sales-capacity spending fails to convert.
• Monitor TWLO, ZETA and HUBS around their next results for customer-engagement budget signals. Broad demand weakness across these peers would argue against a BRZE-specific share-gain thesis; BRZE outperformance alongside peer weakness would strengthen the competitive-takeaway case.
• Do not treat analyst targets as a catalyst. Require disclosure support from dollar-based net retention, enterprise customer growth and sales productivity before underwriting AI as incremental revenue rather than a feature-set defense.